Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans
Reuters2026/08/05 12:07- Compass Pathways outlined plans to file a rolling NDA for COMP360 psilocybin in treatment-resistant depression, targeting completion in Q4 2026.
- U.S. launch targeted for H1 2027, contingent on FDA clearance; Breakthrough Therapy designation cited alongside a Priority Review Voucher in TRD.
- Two Phase 3 trials, COMP005 and COMP006, met the primary endpoint on MADRS change at Week 6 with P<0.001.
- Company highlighted durability through 26 weeks with infrequent dosing; additional dosing described as deepening response in some patients.
- Commercial rollout planning centers on certified treatment sites, REMS readiness, specialty pharmacy or buy-and-bill distribution, payer engagement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
